NEW YORK (GenomeWeb News) - SurModics, a developer of drug-delivery and surface-modification technologies, said this week that it has acquired BioFX Laboratories in a deal worth up to $22.7 million.  
The agreement calls for SurModics to pay $11.3 million for BioFX, which makes substrates used by the in vitro diagnostics industry. SurModics said it could pay an additional $11.4 million on the achievement of certain revenue targets. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.